Blood cancer drug besponsa under safety review in korean study
NCT ID NCT04307134
First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 21 times
Summary
This study looked at the safety and effectiveness of the drug Besponsa in 108 people in Korea with a relapsed or hard-to-treat type of blood cancer called B-cell ALL. Researchers tracked side effects and how well the drug worked in everyday medical practice. The goal was to confirm the drug's safety after it was already approved for use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.